Valuation: EnteroMedics Inc

Market Cap 15.37M 13.47M 12.48M 11.49M 21.67M 1.48B 21.93M 149M 58.3M 725M 57.7M 56.46M 2.5B P/E 2026 *
-3.11x
P/E 2027 * -2.39x
Enterprise Value 15.37M 13.47M 12.48M 11.49M 21.67M 1.48B 21.93M 149M 58.3M 725M 57.7M 56.46M 2.5B EV / Sales 2026 *
102x
EV / Sales 2027 * 61.5x
Free-Float
-
Yield 2026 *
-
Yield 2027 * -

Financials

2026 *2027 *
Net sales 150K 131K 122K 112K 211K 14.45M 214K 1.45M 569K 7.08M 563K 551K 24.45M 250K 219K 203K 187K 352K 24.08M 357K 2.42M 948K 11.8M 938K 918K 40.74M
Net income -4.89M -4.29M -3.97M -3.66M -6.89M -471M -6.98M -47.4M -18.55M -231M -18.36M -17.96M -797M -7.77M -6.81M -6.31M -5.81M -10.95M -748M -11.08M -75.3M -29.47M -367M -29.16M -28.54M -1.27B
Net Debt - -
Logo EnteroMedics Inc
ReShape Lifesciences Inc. is a weight-loss and metabolic health-solutions company. The Company offers an integrated portfolio of products and services that manage and treat obesity and metabolic disease. Its Lap-Band System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures, such as gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation (DBSN) system utilizes a vagus nerve block and stimulation technology platform for the treatment of type II diabetes and metabolic disorders. The Obalon balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. Its ReShape Calibration tubes are multifunctional devices compared to reusable bougies and disposable gastric tubes. Its Lap-Band 2.0, like the original Lap-Band System, is designed to provide minimally invasive long-term treatment of severe obesity.
Employees
-
Sector
-